--- title: "Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing" type: "News" locale: "en" url: "https://longbridge.com/en/news/283226504.md" description: "Ascletis Pharma (SEHK:1672) has selected its ASC30_39 obesity therapy candidate for clinical development, planning to file an IND with the U.S. FDA by Q3 2026. The company's shares have risen 25.03% over the past 30 days, with a current price of HK$18.48, but it trades at a high P/B ratio of 8.8x, above the industry average of 5.3x, indicating potential overvaluation. Despite ongoing losses of CN¥359.88m and limited revenue, market expectations remain high. Investors are advised to consider risks and explore other investment opportunities." datetime: "2026-04-18T13:54:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283226504.md) - [en](https://longbridge.com/en/news/283226504.md) - [zh-HK](https://longbridge.com/zh-HK/news/283226504.md) --- # Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing Ascletis Pharma (SEHK:1672) announced the selection of its ASC30\_39 fixed dose combination obesity therapy candidate for clinical development. The company plans to file an IND with the U.S. FDA in the third quarter of 2026. See our latest analysis for Ascletis Pharma. That obesity announcement comes after a strong run in the shares, with the latest price at HK$18.48, a 30 day share price return of 25.03% and a 1 year total shareholder return of 274.09%. This suggests momentum has been building over both shorter and longer periods. If this kind of biotech progress has your attention, it may be worth widening your search to other healthcare names using our screener for 127 healthcare AI stocks After a rally that has lifted the shares very sharply over 1 and 3 years, and with a price still sitting below the HK$22.19 analyst target, investors may wonder whether there is still an opportunity here or if the market is already pricing in future growth. ## Price to Book of 8.8x: Is It Justified? Ascletis Pharma trades on a P/B of 8.8x which is above the Hong Kong biotechs industry average of 5.3x, even after the strong share price run to HK$18.48. P/B compares the HK$18.48 market value of each share with the company’s book value per share on the balance sheet, so it is often used for asset heavy or early stage companies where earnings are not yet a useful guide. For Ascletis Pharma, the 8.8x P/B suggests investors are paying a higher price than the sector average for each unit of net assets, despite the company being unprofitable and reporting a loss of CN¥359.88m alongside limited revenue of roughly CN¥2m. That points to expectations around the pipeline, future approvals or commercialisation outcomes rather than current financial performance. Compared with the industry’s 5.3x, the premium P/B multiple is substantial and indicates the market is assigning a richer value to Ascletis Pharma’s balance sheet and prospects than to the typical Hong Kong biotech peer. See what the numbers say about this price — find out in our valuation breakdown. **Result: Price to book of 8.8x (OVERVALUED)** However, there are clear risks to keep in mind, including ongoing CN¥359.88m losses and the possibility that key pipeline programmes face trial setbacks or delays. Find out about the key risks to this Ascletis Pharma narrative. ## Next Steps With sentiment clearly mixed between excitement and caution, it makes sense to review the data yourself and act quickly while forming your own view using the 1 key reward and 2 important warning signs ## Looking for more investment ideas? If Ascletis Pharma has you thinking about what else might be worth attention, do not stop here; broaden your watchlist before the next wave of opportunities breaks. - Target potential mispricing by scanning for companies that combine quality and attractive valuations through the 234 high quality undervalued stocks. - Strengthen your income stream by checking out businesses offering robust yields among the 475 dividend fortresses. - Prioritise resilience by focusing on companies with healthy finances using the 295 resilient stocks with low risk scores. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [01672.HK](https://longbridge.com/en/quote/01672.HK.md) ## Related News & Research - [Assessing Ascletis Pharma (SEHK:1672) Valuation After New ASC37 Obesity Candidate Advances Toward FDA IND Filing](https://longbridge.com/en/news/268739926.md) - [Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials](https://longbridge.com/en/news/274573426.md) - [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md) - [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md) - [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)